Hemab Therapeutics (NASDAQ:COAG) Trading Down 7.4% – What’s Next?

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) dropped 7.4% during trading on Wednesday . The stock traded as low as $25.00 and last traded at $25.01. Approximately 77,936 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 207,198 shares. The stock had previously closed at $27.00.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on COAG. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective for the company. Jefferies Financial Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price objective for the company. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Hemab Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Hemab Therapeutics Stock Down 7.9%

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Activity at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the transaction, the director owned 6,149,096 shares in the company, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.